Cardinal Health
CAH
$0.00
-1.99%
Cardinal Health, Inc. is a leading pharmaceutical wholesaler and medical-surgical products distributor, operating within the highly consolidated US healthcare distribution industry. The company is one of the 'Big Three' alongside Cencora and McKesson, collectively controlling over 90% of the pharmaceutical wholesale market, giving it significant scale and a stable, albeit low-margin, core business. The current investor narrative centers on the stock's sharp volatility following its most recent earnings report, where a revenue miss triggered a sell-off despite the company beating profit expectations and raising its full-year outlook, highlighting the market's focus on growth sustainability and margin execution in a competitive, high-volume sector.…
CAH
Cardinal Health
$0.00
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating: Hold. The core thesis is that while Cardinal Health possesses strong cash flows and a dominant market position, its elevated valuation, margin volatility, and leveraged balance sheet create a balanced risk/reward profile that favors waiting for a better entry point or clearer signs of margin stabilization.
Supporting evidence includes: 1) A forward PE of 18.66x, which prices in significant earnings growth but is not egregious for a market leader; 2) Robust revenue growth of 18.42% YoY, demonstrating business momentum; 3) Exceptional free cash flow generation of $5.51 billion TTM, supporting the dividend and buybacks; and 4) A consensus analyst stance that is bullish with an implied target offering ~49% upside, indicating professional optimism about the company's guidance.
The biggest risks are margin erosion below 0.7% and a deterioration in liquidity from the already tight current ratio of 0.94. This Hold would upgrade to a Buy if the forward PE compresses below 16x (offering a larger margin of safety) or if net margins demonstrate sequential expansion above 1.0% for two consecutive quarters. It would downgrade to a Sell if revenue growth decelerates below 10% YoY or if free cash flow turns negative. Relative to its own history and the low-margin distribution peer group, the stock is fairly valued to slightly overvalued, as the market is paying for expected earnings growth that has yet to materialize consistently.
Sign up to view all
CAH 12-Month Price Forecast
The outlook for CAH is one of cautious optimism tempered by fundamental constraints. The company's scale and cash generation are undeniable strengths, but the investment case is hamstrung by margin fragility and financial leverage. The base case (60% probability) of modest appreciation to the $280-$310 range is most likely, predicated on the company hitting its EPS targets without major setbacks. The stance is neutral because the significant analyst upside (~49%) is counterbalanced by high execution risk in a low-margin business. We would upgrade to bullish on evidence of sustained margin improvement (net margin >1%) and downgrade to bearish on a breakdown below the key technical support of $182.50.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
6 analysts
Implied Upside
—
vs. current price
Analyst Count
6
covering this stock
Price Range
$0 - $0
Analyst target range
Cardinal Health is covered by a modest cohort of 6 analysts, indicating solid but not overwhelming institutional interest. The consensus sentiment leans bullish, as evidenced by recent institutional ratings where firms like Barclays, Wells Fargo, Mizuho, and Morgan Stanley maintain 'Overweight' or 'Outperform' ratings, and Citigroup upgraded to 'Buy' in January 2026. The average target price is derived from estimated EPS and revenue figures, implying a target based on a forward PE multiple applied to the consensus EPS of $17.92. With a current price of $223.85 and a forward PE of 18.66x, the implied consensus price target is approximately $334, suggesting significant upside potential, though this calculation is inferred as a direct average target price is not provided in the data. The target range, implied by EPS estimates, is wide, with a low EPS of $17.40 and a high of $18.34. The high target likely assumes successful execution on raised profit guidance, margin expansion, and stable pharmaceutical pricing. The low target likely factors in risks such as competitive pressures, reimbursement headwinds, or further revenue volatility. The wide spread between high and low estimates signals a degree of uncertainty among analysts regarding the company's near-term earnings power, which is consistent with the stock's recent price volatility following its mixed earnings report.
Bulls vs Bears: CAH Investment Factors
The evidence tilts slightly bullish, primarily driven by strong analyst conviction, significant implied upside, robust cash generation, and a recovery in price momentum. However, the bear case presents substantial fundamental risks centered on financial leverage, margin fragility, and market sensitivity to revenue volatility. The single most important tension in the investment debate is whether the company's massive scale and cash flow can consistently overcome its razor-thin, volatile margins and leveraged balance sheet to deliver the earnings growth implied by its forward valuation. The resolution of this tension—specifically, the stabilization and expansion of net margins from the current 0.72%—will be the primary determinant of the stock's performance.
Bullish
- Strong Free Cash Flow Generation: The company generates substantial cash, with $5.51 billion in TTM free cash flow and $555 million in the latest quarter. This robust cash generation provides flexibility for shareholder returns, debt reduction, and strategic investments, underpinning the stock's 1.2% dividend yield.
- Analyst Consensus Bullish with High Upside: The analyst community is bullish, with major firms like Citigroup, Morgan Stanley, and Barclays maintaining 'Buy' or 'Overweight' ratings. The implied consensus price target of ~$334, based on a forward PE of 18.66x and EPS of $17.92, suggests nearly 49% upside from the current price of $223.85.
- Solid Revenue Growth and Market Dominance: Cardinal Health posted 18.42% YoY revenue growth in its latest quarter to $65.44 billion, driven by its core Pharmaceutical segment ($60.67B). As part of the 'Big Three' controlling over 90% of the US wholesale market, it benefits from immense scale and a stable, recurring revenue base.
- Attractive Forward Valuation: The stock trades at a forward PE of 18.66x, a significant discount to its trailing PE of 25.94x, implying the market expects strong earnings growth. Its Price-to-Sales ratio of 0.18 and EV/Sales of 0.23 are extremely low, reflecting a high-volume business model that is not overvalued on a sales basis.
Bearish
- Extremely Thin and Volatile Margins: The company operates on razor-thin margins, with a gross margin of 3.38% and a net margin of 0.72% in the latest quarter. These margins are highly volatile, as seen in the sequential drop from 3.62% (Q1 2026) and 3.86% (Q3 2025), exposing earnings to minor cost pressures.
- Negative Shareholder Equity and High Leverage: The company has negative shareholder equity, resulting in a negative Debt-to-Equity ratio of -3.36 and a negative ROE of -56.13%. This indicates a highly leveraged capital structure reliant on debt and intangible assets, which increases financial risk.
- Market Punishes Revenue Misses Severely: The stock's sharp 20.61% max drawdown and recent volatility were triggered by a Q2 revenue miss, despite beating profit expectations and raising guidance. This highlights the market's intense focus on top-line growth sustainability in this low-margin business, making the stock prone to sharp corrections.
- Tight Liquidity and High Working Capital Needs: The current ratio of 0.94 indicates a tight liquidity position, which is typical for distributors managing massive working capital. This limits financial flexibility and increases sensitivity to interest rate changes and supply chain disruptions.
CAH Technical Analysis
The stock is in a sustained long-term uptrend but has recently experienced significant volatility and a sharp correction. Over the past year, CAH has delivered a strong 39.45% price appreciation, yet its current price of $223.85 sits at approximately 74% of its 52-week range ($137.75 to $233.60), indicating a retreat from recent highs after a powerful rally. This positioning suggests the momentum has cooled, with the stock now consolidating after testing resistance near its 52-week peak. Recent momentum shows a dramatic divergence: the stock surged 20.12% over the past month, sharply contrasting with a more modest 3.12% gain over the past three months. This 1-month surge, which significantly outperformed the S&P 500's -0.08% return, represents a strong recovery from the April/May sell-off but may also indicate a volatile, news-driven rebound rather than a resumption of the steady uptrend. The stock's beta of 0.526 indicates it is approximately 47% less volatile than the broader market, which is typical for a stable distribution business, though recent price swings have been pronounced. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $233.60 and support at the 52-week low of $137.75. A decisive breakout above $233.60 would signal a renewal of bullish conviction, while a breakdown below the recent May low of $182.50 could indicate a deeper correction is underway.
Beta
0.53
0.53x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$138-$234
Price range past year
Annual Return
+34.1%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | +10.7% | +0.7% |
| 3m | +6.7% | +15.1% |
| 6m | +9.3% | +9.7% |
| 1y | +34.1% | +25.0% |
| ytd | +7.8% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Cardinal Health's revenue trajectory shows robust growth, albeit with some quarterly volatility. For the quarter ending December 31, 2025, revenue reached $65.44 billion, representing a substantial 18.42% year-over-year growth. This growth is primarily driven by its massive Pharmaceutical segment, which contributed $60.67 billion in the latest period, underscoring its dominance within the company's portfolio. However, sequential trends show revenue dipped from $64.01 billion in the prior quarter (Q1 2026), indicating potential lumpiness in contract timing or pricing. The company is profitable but operates on razor-thin margins characteristic of the distribution industry. Net income for the latest quarter was $471 million, resulting in a net margin of just 0.72%. The gross margin was 3.38%, while the operating margin was 1.08%. These margins have shown some fluctuation quarter-to-quarter; for instance, gross margin was 3.62% in Q1 2026 and 3.86% in Q3 2025, reflecting the competitive and price-sensitive nature of the business. The balance sheet and cash flow picture is mixed, marked by strong operating cash generation but a leveraged structure. The company generated $686 million in operating cash flow and $555 million in free cash flow for its latest quarter. The trailing twelve-month free cash flow is a robust $5.51 billion. However, the debt-to-equity ratio is negative at -3.36 due to negative shareholder equity, a common feature for firms with large share buyback programs and intangible asset write-downs. The current ratio of 0.94 indicates a tight liquidity position, which is typical for distributors managing high working capital needs.
Quarterly Revenue
$65.4B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given that Cardinal Health has positive net income ($471 million last quarter), the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 25.94x and a forward PE of 18.66x. The significant discount of the forward PE implies the market expects substantial earnings growth in the coming year, aligning with the company's raised profit guidance. Compared to sector averages, Cardinal Health's valuation presents a nuanced picture. Its Price-to-Sales (PS) ratio of 0.18 is extremely low, reflecting the high-volume, low-margin business model. The Enterprise Value-to-Sales (EV/Sales) of 0.23 also suggests the market is not assigning a high premium for its revenue base. The forward PE of 18.7x is likely at a discount to more asset-light healthcare peers but may be in line with other distributors, though specific industry average data is not provided for a precise comparison. Historically, the stock's own valuation has been volatile. The current trailing PE of 25.94x is above its recent historical range observed in the provided data, which has fluctuated between approximately 14x and 42x over the past several quarters. Trading near the higher end of this band suggests the market is currently pricing in relatively optimistic expectations for earnings stability and growth, potentially leaving less room for multiple expansion unless execution improves markedly.
PE
25.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -450x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. Cardinal Health operates on extremely thin margins (net margin 0.72%), making earnings highly sensitive to minor cost increases or pricing pressure. The balance sheet is leveraged, with negative shareholder equity (-$14.56 book value per share) and a Debt-to-Equity ratio of -3.36, indicating reliance on debt and intangible assets. While free cash flow is strong at $5.51 billion TTM, the current ratio of 0.94 signals tight liquidity for managing its high working capital needs, typical of distributors.
Market & Competitive Risks include valuation compression, as the stock trades at a trailing PE of 25.94x, near the higher end of its recent historical range. The market has shown zero tolerance for revenue misses, as evidenced by the April sell-off despite raised profit guidance. The stock's low beta of 0.526 offers some insulation from broad market swings, but it remains exposed to sector-specific risks like pharmaceutical reimbursement changes and competitive pressures within the consolidated 'Big Three' wholesale market.
Worst-Case Scenario involves a combination of sustained margin compression, a significant contract loss, and a broader market downturn. This could trigger analyst downgrades, multiple compression towards the lower end of its historical PE range (~14x), and a retest of its 52-week low. From the current price of $223.85, a decline to the 52-week low of $137.75 represents a catastrophic loss of approximately -38.5%. A more realistic severe bear case, aligning with the stock's recent May low of $182.50, would imply a downside of approximately -18.5%.
FAQ
The key risks are: 1) Financial Risk: Highly leveraged balance sheet with negative shareholder equity (D/E of -3.36) and tight liquidity (Current Ratio 0.94). 2) Operational Risk: Extremely thin and volatile profit margins (net margin 0.72%), making earnings highly sensitive to cost pressures. 3) Market Sentiment Risk: The stock has proven vulnerable to sharp corrections on revenue misses, as seen in April 2026, despite beating profit expectations. 4) Sector Risk: Exposure to pharmaceutical pricing and reimbursement pressures within a consolidated, competitive wholesale market. The financial and operational margin risks are the most severe, as they directly impact the company's ability to service debt and grow earnings.
The 12-month forecast centers on a base case target range of $280-$310 (60% probability), implying roughly 25-38% upside from $223.85. This scenario assumes the company meets its raised EPS guidance (~$17.92) and the forward PE multiple holds around 18x-19x. A bull case (25% probability) could see the stock rise to $334-$350 if margin expansion occurs, while a bear case (15% probability) could see a decline to $182-$210 if margins compress further. The most likely outcome is moderate appreciation, driven by earnings growth meeting expectations, but the wide target ranges reflect the underlying volatility and execution risk in the business model.
CAH's valuation is mixed, leaning towards fairly valued to slightly overvalued on a trailing basis but potentially undervalued on a forward-looking basis. The trailing PE of 25.94x is at the higher end of its own recent historical range. However, the forward PE of 18.66x represents a discount and implies the market expects strong earnings growth. Extremely low sales multiples (PS of 0.18) reflect the low-margin business model, not necessarily undervaluation. Compared to likely distribution peers, its forward multiple is probably in line. The valuation implies the market is paying for future earnings growth that must be delivered to justify the current price.
CAH presents a nuanced opportunity. For investors comfortable with moderate risk, it offers a strong market position, robust cash flow ($5.51B TTM), and significant analyst upside (~49% to implied targets). However, it is not a clear-cut 'good buy' for all due to its thin margins (0.72% net), leveraged balance sheet (Negative D/E), and history of sharp sell-offs on revenue misses. It is a good buy for investors who believe the company can execute on its raised profit guidance and stabilize margins, and who are willing to accept volatility. A more conservative approach would be to wait for a pullback below $210 to improve the margin of safety.
CAH is more suitable for a long-term investment horizon of 3-5 years. Its low beta (0.526) and stable, recurring revenue base from a dominant market position support a long-term hold thesis focused on cash flow compounding and dividend growth. However, short-term trading is challenged by the stock's recent volatility and sensitivity to quarterly revenue prints. The long-term horizon allows investors to look through quarterly noise and benefit from the company's scale and cash generation. A minimum holding period of 12-18 months is suggested to allow the company's earnings growth story to potentially unfold and mitigate the impact of any near-term volatility.